Does Rallies show Form 4 insider transactions for COCH?

Yes. Rallies tracks COCH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is COCH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for COCH. It does not provide personalized investment advice.

COCH (Envoy Medical, Inc. Class A Common Stock) Stock Analysis - Insider Trades

Envoy Medical, Inc. Class A Common Stock (COCH) is a publicly traded Healthcare sector company. As of May 20, 2026, COCH trades at $0.73 with a market cap of $54.86M and a P/E ratio of -0.60. COCH moved +0.00% today. Year to date, COCH is +6.37%; over the trailing twelve months it is -56.47%. Its 52-week range spans $0.36 to $3.60. Analyst consensus is buy with an average price target of $2.50. Rallies surfaces COCH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading COCH stock inside the company?

Recent COCH insider activity includes Patel Mona Chetan bought 312.50K, Potashnick Robert bought 212.50K, Kantor Susan bought 96.15K, BRYNELSEN CHARLES bought 1.00M, and Lucas Brent T. bought 62.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

COCH Key Metrics

Key financial metrics for COCH
Metric	Value
Price	$0.73
Market Cap	$54.86M
P/E Ratio	-0.60
EPS	$-1.23
Dividend Yield	0.00%
52-Week High	$3.60
52-Week Low	$0.36
Volume	32.36K
Avg Volume	0
Revenue (TTM)	$241.00K
Net Income	$-23.76M
Gross Margin	-262.66%

Recent COCH Insider Trades

Patel Mona Chetan bought 312.50K (~$125.00K) on Feb 12, 2026.
Potashnick Robert bought 212.50K (~$85.00K) on Feb 12, 2026.
Kantor Susan bought 96.15K (~$38.46K) on Feb 12, 2026.
BRYNELSEN CHARLES bought 1.00M (~$400.00K) on Feb 12, 2026.
Lucas Brent T. bought 62.50K (~$25.00K) on Feb 12, 2026.

Latest COCH News

Envoy Medical Secures Four Patents Covering Implantable Cochlear Systems, Battery Safety — May 20, 2026
Envoy Medical Completes Activation for 56 Acclaim Implant Patients, Eyes FDA PMA — Apr 22, 2026
Envoy Medical Appoints McKhann After $1.16B, $615M Exits; Acclaim® Trial Complete — Apr 16, 2026
Envoy Medical Gets FDA Nod for Final Acclaim Trial Stage, Wipes Out $32M Debt — Mar 23, 2026
Envoy Medical Hits 56-Patient Enrollment Milestone in Acclaim Trial — Mar 11, 2026

COCH Analyst Consensus

1 analysts cover COCH: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.50.

Common questions about COCH

Who is trading COCH stock inside the company?: Recent COCH insider activity includes Patel Mona Chetan bought 312.50K, Potashnick Robert bought 212.50K, Kantor Susan bought 96.15K, BRYNELSEN CHARLES bought 1.00M, and Lucas Brent T. bought 62.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for COCH?: Yes. Rallies tracks COCH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is COCH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for COCH. It does not provide personalized investment advice.